Virobay
Virobay Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on developing and commercializing novel therapies for various medical conditions, including neuropathic pain, autoimmune diseases, liver fibrosis, cancer, and Alzheimer's disease. The company's pipeline includes VBY-129, a cathepsin S inhibitor aimed at treating neuropathic pain and Crohn's disease, and VBY-376, an orally-administered cathepsin B inhibitor for liver fibrosis associated with nonalcoholic steatohepatitis. Additionally, VBY-825 is designed to inhibit multiple cathepsins to mitigate autoimmune attacks on bile ducts and reverse fibrosis. Virobay has also licensed VBY-891 to LEO Pharma A/S for specific dermatological uses, such as psoriasis. Founded in 2006, Virobay is dedicated to addressing significant unmet medical needs through its cysteine cathepsin platform, which focuses on developing safer and more effective treatments by regulating essential cellular processes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.